Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study
David Thein, M. Christiansen, Ulrik M. Mogensen, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
Takayuki Yamada, Mako Wakabayashi, Abhinav Bhalla, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 112
From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
Ofri Mosenzon, Stefano Del Prato, Meir Schechter, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 51
Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes
Daniel Edmonston, Hillary Mulder, Elizabeth Lydon, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 8, pp. 696-708
Closed Access | Times Cited: 6
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes
Rohan Khera, Arya Aminorroaya, Lovedeep S Dhingra, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 10, pp. 904-917
Closed Access | Times Cited: 5
Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials
Edoardo Mannucci, Besmir Nreu, Chiara Montereggi, et al.
Nutrition Metabolism and Cardiovascular Diseases (2021) Vol. 31, Iss. 10, pp. 2745-2755
Closed Access | Times Cited: 31
Primary Occurrence of Cardiovascular Events After Adding Sodium–Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes
Tadarro L. Richardson, Alese E. Halvorson, Amber J. Hackstadt, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 6, pp. 751-760
Open Access | Times Cited: 11
Dipeptidyl peptidase-4 inhibitors versus sulfonylureas on the top of metformin in patients with diabetes and acute myocardial infarction
Ae‐Young Her, Byoung Geol Choi, Seung‐Woon Rha, et al.
Cardiovascular Diagnosis and Therapy (2024) Vol. 14, Iss. 1, pp. 38-50
Open Access | Times Cited: 4
Medication time of metformin and sulfonylureas and incidence of cardiovascular diseases and mortality in type 2 diabetes: a pooled cohort analysis
Mansour Bahardoust, Farzad Hadaegh, Yadollah Mehrabi, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Blueness, Whiteness, and greenness Appraisal of sensitive chromatographic approach for determination of semaglutide concurrently with Pioglitazone and metformin using green mobile Phase; alongside with pharmacokinetic study
Noura M. Mansour, Amal A. El‐Masry, Dina T. El-Sherbiny, et al.
Microchemical Journal (2024), pp. 111686-111686
Closed Access | Times Cited: 3
Cardiovascular and mortality outcomes of DPP-4 inhibitors vs. sulfonylureas as metformin add-on therapy in patients with type 2 diabetes: A systematic review and meta-analysis
Rumina Hasan, Uliana Y. Chugaeva, Mahdi Mohammadian, et al.
PLoS ONE (2025) Vol. 20, Iss. 5, pp. e0321032-e0321032
Open Access
The function, mechanisms, and clinical applications of metformin: potential drug, unlimited potentials
Jianhong Liu, Ming Zhang, Dan Deng, et al.
Archives of Pharmacal Research (2023) Vol. 46, Iss. 5, pp. 389-407
Closed Access | Times Cited: 9
Is Time-Restricted Eating Safe in the Treatment of Type 2 Diabetes?—A Review of Intervention Studies
Sarah Uldal, Kim Katrine Bjerring Clemmensen, Frederik Persson, et al.
Nutrients (2022) Vol. 14, Iss. 11, pp. 2299-2299
Open Access | Times Cited: 14
Sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real‐world clinical practice? A systematic review and meta‐analysis of observational studies
William Hinton, Abdus Samad Ansari, Martin Whyte, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 2, pp. 501-515
Closed Access | Times Cited: 9
Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: A nationwide cohort study of patients with type 2 diabetes
Jui Wang, Hon‐Yen Wu, Kuo‐Liong Chien
Diabetes & Metabolism (2021) Vol. 48, Iss. 3, pp. 101299-101299
Closed Access | Times Cited: 11
Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM Study
Rohan Khera, Arya Aminorroaya, Lovedeep S Dhingra, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus DPP-4 inhibitors. An Italian real-world study in the context of other observational studies
Enrico Longato, Benedetta Maria Bonora, Barbara Di Camillo, et al.
Diabetes Research and Clinical Practice (2021) Vol. 179, pp. 109024-109024
Closed Access | Times Cited: 9
Heart Failure and Diabetes Mellitus: Biomarkers in Risk Stratification and Prognostication
Michael Lichtenauer, Peter Jirak, Vera Paar, et al.
Applied Sciences (2021) Vol. 11, Iss. 10, pp. 4397-4397
Open Access | Times Cited: 6
Effect of Add-On Therapy of Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors on Adipokines in Type 2 Diabetes Mellitus
Abid Shaheer, Ashok Kumar, P.B. Menon, et al.
Journal of Clinical Medicine Research (2021) Vol. 13, Iss. 6, pp. 355-362
Open Access | Times Cited: 5
Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
Carlos Campos, Jeff Unger
Postgraduate Medicine (2021) Vol. 133, Iss. 8, pp. 843-853
Open Access | Times Cited: 5
UM OLHAR SOBRE A ASSISTÊNCIA NA ATENÇÃO PRIMÁRIA À SAÚDE

(2024)
Open Access
PERCEPÇÕES DE GERENTES, PROFISSIONAIS E USUÁRIOS SOBRE AS PRÁTICAS INTEGRATIVAS E COMPLEMENTARES OFERTADAS NA ATENÇÃO PRIMÁRIA À SAÚDE
Pedro Henrique Brito da Silva, Leylaine Christina Nunes de Barros, Charles Britto Oliveira Gomes, et al.
(2024), pp. 119-153
Open Access
ATUAÇÃO NA ATENÇÃO PRIMÁRIA À SAÚDE DURANTE A PANDEMIA DA COVID-19: RELATO DE EXPERIÊNCIA
Diego da Silva Ferreira, Tallys Newton Fernandes de Matos, Rosiane Barros Pereira, et al.
(2024), pp. 48-62
Open Access
Evaluating Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) in Type 2 Diabetes Mellitus: A Systematic Review
Chithra Sreenivasan, Aneri Parikh, Aida J Francis, et al.
Cureus (2024)
Open Access
Impact of genetic variations of gene involved in regulation of metabolism, inflammation and coagulation on pathogenesis of cardiac injuries associated with COVID-19
HariOm Singh, Aishwarya Nair, Supriya D. Mahajan
Pathology - Research and Practice (2024) Vol. 263, pp. 155608-155608
Closed Access
Cardiovascular Events and Heart Failure in Patients with Type 2 Diabetes Treated with Dipeptidyl Peptidase-4 Inhibitors: An Update Systematic Review and Meta-Analysis
Adili Tuersun, Guanxin Hou, Gang Cheng
(2023)
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top